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ABSTRACT
The responsible human leukocyte antigen (HLA) locus and the role of killer immunoglobulin-like receptor
(KIR) ligand matching on transplantation outcome were simultaneously identified by multivariate analysis in
1790 patients with leukemia who underwent transplantation with T-cell–replete marrow from an unrelated
donor (UR-BMT) through the Japan Marrow Donor Program. The graft-versus-leukemia (GVL) effect
depended on leukemia cell type. HLA-C mismatch reduced the relapse rate in acute lymphoblastic leukemia
(ALL) (hazard ratio [HR]  0.47; P  .003), and HLA-DPB1 mismatch reduced it in chronic myeloid leukemia
(CML) (HR  0.35; P < .001). In contrast, KIR2DL ligand mismatch in the graft-versus-host (GVH) direction
(KIR-L-MM-G) increased in ALL (HR 2.55; P .017). An increased rejection rate was observed in KIR2DL
ligand mismatch in the host-versus-graft direction (HR  4.39; P  .012). Acute GVH disease (GVHD) was
increased not only in the mismatch of HLA-A, -B, -C, and -DPB1, but also in KIR-L-MM-G. As a whole, the
mismatch of HLA-A, -B, and -DQB1 locus and KIR-L-MM-G resulted in increased mortality. In conclusion,
not only the mismatch of HLA-C and -DPB1, but also KIR-L-MM-G affected leukemia relapse, which should
be considered based on leukemia cell type. Furthermore, KIR-L-MM induced adverse effects on acute GVHD
(aGVHD) and rejection, and brought no survival benefits to patients with T-cell–replete UR-BMT.
© 2007 American Society for Blood and Marrow Transplantation
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m
o
nNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (HSCT) from a human leukocyte antigen (HLA)- datched unrelated (UR) donor has been established as
ne mode of curative therapy for hematologic malig-
ancies and other hematologic or immunologic disor-
ers [1,2]. Extensive research on genetic factors such
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3s HLA has produced mounting evidence of the pres-
nce of HLA alleles that drastically affect HSCT out-
ome through T cells. Induction of the graft-versus-
eukemia (GVL) effect to reduce relapse of leukemia is
onsidered an advantage of allogeneic HSCT [3].
here have been several large-scale analyses of UR-
SCT. The Japan Marrow Donor Program
JMDP) demonstrated the effect of matching of
LA class I alleles (HLA-A, -B, and -C) on the
evelopment of severe acute graft-versus-host dis-
ase (aGVHD) and the importance of HLA-A and
B allele matching for better survival in T-cell–
eplete UR-HSCT [4,5]. The Fred Hutchinson
ancer Research Center and the US National Mar-
ow Donor Program (NMDP) reported the impor-
ance of HLA class II matching in GVHD and
urvival [6,7]. Updated analysis of the NMDP indi-
ated that HLA-A allele-level mismatching, HLA-B
erologic mismatching, and HLA-DRB1 mismatch-
ng are signiﬁcant risk factors for severe aGVHD,
nd that disparity in HLA class I (HLA-A, -B, or
C) and/or HLA-DRB1 increased the mortality [8].
urthermore, the role of HLA-DPB1 matching has
een elucidated for aGVHD [9-11] and leukemia
elapse [12]. However, the aforementioned reports
ave produced considerable conﬂicting results.
It has become evident that natural killer (NK) cells
nd the subpopulation of T cells express NK cell
eceptors, and that the activity of NK cells is con-
rolled by the recognition of HLA class I molecules on
he target cells by NK cell inhibitory and activating
eceptors [13,14]. The genotype and haplotype of the
iller immunoglobulin-like receptors (KIRs) have
een identiﬁed, and ligand speciﬁcities of KIRs have
een characterized. C1 speciﬁcity of the HLA-C
pitope (Asp80) is the ligand of inhibitory
IR2DL2/3, C2 speciﬁcity (Lys80) is the ligand of
nhibitory KIR2DL1, and HLA-Bw4 is the ligand of
IR3DL1. With allogeneic HSCT, the disparities of
hese receptors between donor and recipient are sus-
ected to induce transplant-related immunologic
vents through activation of NK cells, and evidence of
he clinical outcome of HSCT in relation to KIR
isparities has been accumulated [15]. However, re-
orts of KIR ligand matching in UR-HSCT have
hown contradictory results [16]. Limited patient
umbers, different diseases, and various GVHD pro-
hylaxes make it difﬁcult to draw deﬁnite conclusions
rom these studies.
In the present study, the effects of HLA locus and
IR ligand matching were simultaneously analyzed in
eukemia patients receiving T-cell–replete marrow
rom unrelated donors through the JMDP after a
yeloablative conditioning regimen, focusing in par-
icular on the inﬂuence of leukemia cell type on the
VL effect. a
16ATIENTS AND METHODS
atients
A total of 1790 consecutive leukemia patients who
nderwent transplantation with marrow from a sero-
ogically HLA-A, -B, and -DR antigen–matched do-
or in Japan between January 1993 and March 2000
hrough the JMDP were analyzed. No patients receiv-
ng T-cell–depleted marrow and/or antithymocyte
lobulin (ATG) as GVHD prophylaxis were eligible
or this study. Partial HLA-A and -B alleles and com-
lete HLA-DRB1 alleles were identiﬁed as conﬁrma-
ory HLA typing during the coordination process, and
LA-A, -B, -C, -DQB1, and -DPB1 alleles were
etrospectively reconﬁrmed or identiﬁed after trans-
lantation. The ﬁnal clinical survey of these patients
as completed as of June 1, 2005. Informed consent
as obtained from patient and donor according to the
eclaration of Helsinki, and approval was obtained
rom the JMDP and the Institutional Review Board of
he Aichi Cancer Center.
Characteristics of patients and donors are listed in
able 1. The patients’ age ranged from 0 to 59 years
median, 27 years), and donors’ age ranged from 20 to
1 years (median, 35 years). There were 577 patients
ith acute myeloblastic leukemia (AML), of whom
86 underwent transplantation while in ﬁrst complete
emission (CR), 191 who did so while in second or
urther CR, and 200 who did so while in non-CR; 617
atients with acute lymphoblastic leukemia (ALL), of
hom 236 underwent transplantation while in ﬁrst
R, 207 who did so while in second or further CR,
nd 174 who did so while in non-CR; and 596 patients
ith chronic myeloid leukemia (CML), of whom 417
ere in the ﬁrst chronic phase (CP), 34 were in the
econd or further CP, 90 were in the accelerated
hase, and 55 were in the blastic phase. Standard risk
or leukemia relapse was deﬁned as the status of the
rst CR of AML and ALL and the ﬁrst CP of CML at
ransplantation, whereas high risk was deﬁned as a
ore advanced status than standard risk in AML,
LL, and CML.
LA Typing of Patients and Donors
Alleles at the HLA-A, -B, -C, -DRB1, -DQB1,
nd -DPB1 loci were identiﬁed as described previ-
usly [4,5]. HLA 6 locus alleles were typed in 1773
airs, and HLA 5 locus alleles except HLA-DPB1
ere typed in 17 pairs. HLA genotypes of HLA-A, -B,
C, -DQB1, and -DPB1 alleles of patient and donor
ere reconﬁrmed by the Luminex microbead method
100 System; Luminex, Austin, TX) adjusted for the
MDP [17] and in part by the sequencing-based typ-
ng method in 2004 and 2005. As a result, all HLA
lleles that were observed with  0.1% frequency
mong Japanese were identiﬁed. The numbers of
Table 1. Patient characteristics and matching status of HLA allele and KIR2DL ligand
Patient
Number (%)
Patient Age
Median (years)
Patient Sex
Female (%)
Donor Age
Median (years)
Donor Sex
Female (%)
Sex
Match (%)
Stage at Transplant
High (%)
GVHD Prophylaxis
Cyclosporine (%)
Total Body
Irradiation (%)
M/MM* M/MM* M/MM* M/MM* M/MM* M/MM* M/MM* M/MM* M/MM*
All leukemia (n  1790)
HLA-A 1484/306 27/26 39/37 34/33 38/40 57/55 52/57 73/73 83/72
HLA-B 1645/145 27/26 40/34 34/35 39/36 56/63 52/51 72/76 83/84
HLA-C 1256/534 27/26 39/41 34/33 38/40 56/58 52/55 74/70 83/82
HLA-DRB1 1434/356 27/26 40/38 34/34 38/41 57/57 51/60 74/66 83/82
HLA-DQB1 1391/399 27/26 40/38 34/33 38/41 57/57 52/56 74/67 83/83
HLA-DPB1 612/1163 26/27 42/39 34/34 39/39 60/56 50/55 75/71 81/84
KIR2DL-G† 1693/97 26/27 39/35 34/34 39/43 57/74 53/63 73/64 83/84
KIR2DL-R‡ 1679/111 27/25 39/40 34/32 39/60 57/51 53/59 73/67 83/84
Acute myeloblastic leukemia (n  577)
HLA-A 486/91 28/27 44/44 33/33 38/39 58/55 67/71 72/60 81/89
HLA-B 537/40 27/31 45/33 33/35 39/30 56/73 67/83 71/68 83/80
HLA-C 405/172 28/28 43/45 33/34 39/37 56/61 66/73 74/63 82/83
HLA-DRB1 474/103 28/27 44/43 33/33 37/47 58/55 66/77 72/63 82/86
HLA-DQB1 469/108 27/29 45/40 33/33 38/43 57/56 67/72 72/64 83/81
HLA-DPB1 206/366 27/28 48/42 34/33 40/38 58/57 65/70 71/70 81/84
KIR2DL-G† 546/31 28/28 43/55 33/33 38/39 57/65 67/71 72/52 82/83
KIR2DL-R‡ 546/31 28/28 43/55 33/35 38/39 59/32 68/68 71/58 82/83
Acute lymphoblastic leukemia (n  617)
HLA-A 515/102 20/19 41/40 34/32 42/42 55/50 60/69 73/74 91/88
HLA-B 567/50 19/20 41/42 33/36 42/38 54/60 61/70 72/80 91/86
HLA-C 437/180 19/19 41/41 34/32 41/42 54/57 61/63 73/72 91/89
HLA-DRB1 485/132 19/19 41/42 33/33 43/36 55/52 61/64 74/70 90/90
HLA-DQB1 467/150 19/20 41/41 34/33 42/41 55/51 61/63 75/68 90/92
HLA-DPB1 190/425 19/29 43/40 34/33 38/43 61/52 61/62 77/71 89/91
KIR2DL-G† 587/30 20/17 42/20 33/35 42/40 55/53 61/73 73/73 91/83
KIR2DL-R‡ 577/40 19/19 39/40 34/30 42/43 54/53 61/73 73/70 90/93
Chronic myelocytic leukemia (n  596)
HLA-A 483/113 32/31 33/35 34/34 35/40 59/60 29/35 73/81 76/72
HLA-B 541/55 32/29 34/27 34/37 36/38 56/60 29/36 74/78 74/85
HLA-C 414/182 32/31 33/36 35/34 35/39 60/58 30/31 74/76 75/74
HLA-DRB1 475/121 32/33 34/31 34/36 35/40 58/63 27/41 77/64 76/70
HLA-DQB1 455/141 32/31 34/33 35/33 35/39 57/65 28/35 76/69 75/74
HLA-DPB1 216/372 31/33 35/33 34/35 38/34 60/59 28/31 76/73 73/76
KIR2DL-G† 560/36 32/32 34/31 35/32 35/50 59/53 29/44 75/67 71/83
KIR2DL-R‡ 556/40 32/27 34/28 35/31 36/38 59/65 29/38 75/68 75/75
Standard-ﬁrst complete remission or ﬁrst chronic phase; high more advanced stage than standard.
*M/MM match/mismatch in GVH direction for HLA matching.
†KIR2DL ligand mismatching in GVH direction.
‡KIR2DL ligand mismatching in HVG direction.
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3dentiﬁed alleles in this study were 25 in HLA-A, 43 in
LA-B, 20 in HLA-C, 33 in HLA-DRB1, 14 in
LA-DQB1, and 21 in HLA-DPB1.
atching of HLA Allele and KIR2DL Ligand
For the analysis of GVHD and leukemia relapse,
LA allele mismatch among the donor–recipient pair
as scored when the recipient’s alleles were not shared
y the donor (graft-versus-host [GVH] direction). For
raft rejection, HLA allele mismatch among the do-
or–recipient pair was scored when the donor’s alleles
ere not shared by the patient (host-versus-graft
HVG] direction). For survival, the mismatch was
eﬁned as that of either the GVH direction or the
VG direction.
KIR2DL ligand speciﬁcity of HLA-C antigen was
etermined according to the HLA-C allele. The
pitope of HLA-Cw3 group (C1 speciﬁcity) consists
f Asn80, and that of the HLA-Cw4 group (C2 spec-
ﬁcity) consists of Lys80.
KIR ligand mismatch in the GVH direction (KIR-
-MM-G) was scored when the donor’s KIR2DL
pitope of HLA-C was not shared by the patient
pitope. This mismatch occurred when KIR2DL2/3-
r KIR2DL1-positive effector cells were activated
ithout the expression of corresponding HLA-C li-
and (C1 or C2, respectively) on the patient’s target
ells. KIR ligand mismatch in HVG direction (KIR-
-MM-R) was scored when the patient’s KIR2DL
pitope of HLA-C was not shared by the donor. This
ismatch occurred when patient KIR2DL2/3- or
IR2DL1-positive effector cells were activated with-
ut the expression of corresponding HLA-C ligand
C1 or C2, respectively) on donor cells.
atching Status of HLA Locus in Allele Level and
IR2DL Ligand
The matching status of HLA allele matching in
he GVH direction in each HLA locus and KIR ligand
atching in both directions are given in Table 1. The
LA-C epitope of KIR2DL was estimated from
LA-C allele type, with 92.4% of the HLA-C allele
elonging to the Cw3 group (C1 speciﬁcity) and 7.6%
elonging to the Cw4 group (C2 speciﬁcity). KIR2DL
igand match in both directions occurred in 1583 pairs
88.4%). KIR-L-MM-G, which occurred in the com-
ination of KIR2DL ligand in patient–donor pairs,
as found in 97 pairs (5.4%): C1/C1 and C1/C2 in 92
airs, C2/C2 and C1/C2 in 4 pairs, and C1/C1 and
2/C2 in 1 pair. KIR-L-MM-R, which occurred in
he combination of KIR2DL ligand in patient and
onor pairs, was found in 111 pairs (6.2%): C1/C2
nd C1/C1 in 105 pairs, C1/C2 and C2/C2 in 5 pairs,
nd C1/C1 and C2/C2 in 1 pair. Mismatches in both
irections were found in only 1 pair. Because all pairs A
18ere a serologic HLA-B match in this study, the
ombination of KIR3DL1 and its ligand of Bw4
atched in all pairs.
efinition of Transplantation-Related Events
The occurrence of aGVHD was evaluated accord-
ng to grading criteria in patients who survived more
han 8 days after transplantation, and chronic GVHD
cGVHD) according to the criteria in patients who
urvived more than 100 days after transplantation
s described previously [5]. Rejection was deﬁned
s when the peripheral granulocyte count became
500/L with the ﬁnding of severe hypoplastic mar-
ow in engrafted patients. Engraftment was deﬁned as
peripheral granulocyte count of  500/L for 3
uccessive days in patients surviving  21 days after
ransplantation.
VHD Prophylaxis
Among the 1790 patients transplanted with T-
ell–replete marrow, 1302 received a cyclosporine-
ased regimen and 488 received a tacrolimus-based
egimen for GVHD prophylaxis. Anti-thymocyte
lobuline (ATG) was not given for GVHD prophy-
axis.
reconditioning Regimen
All patients were preconditioned with a myeloab-
ative regimen, with 1480 receiving total body irradi-
tion (TBI)-containing regimens and 310 receiving
on-TBI regimens.
tatistical Analysis
All of the analyses were conducted using STATA
ersion 8.2 (STATA Corp, College Station, TX).
verall survival rate was assessed by the Kaplan-Meier
roduct limit method [18]. Cumulative incidences of
GVHD, cGVHD, rejection, and leukemia relapse
ere assessed as described previously to eliminate the
ffect of competing risk [19,20]. The competing
vents regarding aGVHD, cGVHD, rejection, and
elapse were deﬁned as death without aGVHD,
GVHD, rejection, and relapse, respectively. For each
ndpoint, a log-rank test was applied to assess the
mpact of the factor of interest.
Cox proportional hazard models [21] were applied
o assess the impact of HLA allele matching (mis-
atch vs match [hazard risk  1.0] as a reference
roup) as well as KIR ligand matching (mismatch vs
atch in the GVH direction and mismatch vs match
n the HVG direction) including the following con-
ounders. The confounders considered were sex (do-
or–recipient pairs), patient age (older: linear), donor
ge (older: linear), type of disease (AML, CML, or
LL), risk of leukemia relapse (high vs standard),
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ne-based and ATG vs cyclosporine-based), numbers
f transplanted cells (linear), and preconditioning
non-TBI vs TBI). The numbers of nucleated cells
efore manipulation of bone marrow were replaced
ith the numbers of transplanted cells.
Multivariate analysis for clinical outcomes, includ-
ng KIR ligand matching and HLA-C matching in all
airs (not restricted to HLA-C mismatch), made it
ossible to evaluate whether these factors are indepen-
ent. The results of all pairs by multivariate analysis are
resented in the Results section and in Tables 2, 3, and
. HLA-C–mismatched pairs were selected for the anal-
sis of cumulative incidence in KIR ligand matching.
ESULTS
ffects of HLA Locus Mismatch and KIR Ligand
ismatch on Leukemia Relapse
When all leukemia patients (AML, ALL, and
ML) were analyzed together, HLA-C mismatch was
able 2. Effects of HLA and KIR ligand matching for leukemia relapse
All Leukemia Cell Types
Acute Myelobla
Leukemia
HR* (95% CI) P HR (95% CI)
LA-A 1.19 (0.89-1.59) .251 0.92 (0.54-1.58)
LA-B 1.01 (0.65-1.59) .953 1.36 (0.65-2.88)
LA-C 0.71 (0.53-0.96) .025 0.8 (0.49-1.30)
LA-DRB1 1.05 (0.73-1.53) .789 0.78 (0.40-1.52)
LA-DQB1 1.10 (0.77-1.58) .579 1.55 (0.82-2.95)
LA-DPB1 0.68 (0.55-0.85) .001 0.76 (0.52-1.09)
IR2DL-G† 1.55 (0.92-2.63) .103 1.05 (0.37-3.02)
IR2DL-R‡ 0.73 (0.40-1.34) .313 0.53 (0.15-1.78)
LA matching in GVH direction.
Hazard ratio of mismatch with match as a reference adjusted for pa
irradiation, transplanted cell dose, risk status, and other matchi
KIR2DL ligand mismatching in GVH direction.
KIR2DL ligand mismatching in HVG direction.
able 3. Effects of HLA and KIR ligand matching for acute GVHD, c
Acute GVHD (Grade 2-4)
(n  1751)
Acute GVHD (G
(n  1751
HR* 95% CI P HR 95% CI
LA-A 1.22 (1.02-1.46) .034 1.44 (1.11-1.86)
LA-B 1.43 (1.28-1.82) .003 1.40 (1.00-1.95)
LA-C 1.29 (1.08-1.55) .006 1.39 (1.06-1.83)
LA-DRB1 1.15 (0.90-1.47) .254 1.09 (0.77-1.54)
LA-DQB1 1.02 (0.81-1.29) .871 1.13 (0.81-1.59)
LA-DPB1 1.39 (1.19-1.63) <.001 1.26 (1.00-1.60)
IR2DL-G† 1.70 (1.28-2.26) <.001 2.35 (1.62-3.40)
IR2DL-R‡ 1.04 (0.77-1.42) .78 1.33 (0.88-2.02)
LA matching in GVH direction for acute GVHD and chronic G
Hazard ratio of mismatch with match as a reference adjusted for pa
irradiation, transplanted cell dose, risk status, and other matchi
KIR2DL ligand mismatching in GVH direction.
KIR2DL ligand mismatching in HVG direction.ound to be a factor reducing the relapse rate (HR 
.71; P  .025) (Table 2). This GVL effect was re-
arkable in ALL patients (HR  0.47; P  .003),
specially in high risk (HR  0.40; P  .004) but not
n standard risk (HR 0.85; P .728). No such effect
as observed in AML patients (HR  0.80; P  .366)
r CML patients (HR  1.20; P  .591).
Cumulative incidence curves of relapse by leuke-
ia cell type are shown in Figure 1. The relapse rate
years after transplantation was 16.7% (95% conﬁ-
ence interval [CI]  11.6%-30.9%) for HLA-C mis-
atch and 29.8% (95% CI  25.5%-34.3%) for
LA-C match in ALL patients (P  .012); 17.6%
95% CI  12.2%-23.8%) and 25.9% (95% CI 
1.1%-30.9%), respectively, in AML patients (P 
342); and 11.7% (955 CI 12.2%-23.8%) and 12.0%
95% CI  9.0%-15.4%), respectively, in CML pa-
ients (P  .485).
HLA-DPB1 mismatch was shown to reduce the
verall leukemia relapse rate (HR  0.68; P  .001)
Table 2). This effect was signiﬁcant in CML (HR 
Acute Lymphoblastic
Leukemia Chronic Myeloid Leukemia
HR (95% CI) P HR (95% CI) P
1 1.18 (0.76-1.86) .462 1.63 (0.89-2.97) .114
6 0.98 (0.48-1.98) .952 0.62 (0.22-1.76) .367
6 0.47 (0.28-0.78) .003 1.2 (0.62-2.29) .591
6 0.91 (0.51-1.61) .737 1.25 (0.55-2.85) .59
8 1.11 (0.63-1.95) .71 0.86 (0.39-1.93) .72
7 0.92 (0.65-1.28) .604 0.35 (0.21-0.58) <.001
6 2.55 (1.18-5.52) .017 1.23 (0.38-3.94) .727
5 1.30 (0.53-3.19) .569 0.5 (0.14-1.80) .292
e, donor age, sex-matching disease, GVHD prophylaxis, total body
s of HLA and KIR ligand.
VHD, and rejection in all leukemia cell types
4) Chronic GVHD
(n  1109)
Rejection
(n  1664)
HR 95% CI P HR 95% CI P
006 1.41 (1.08-1.85) .013 0.72 (0.24-2.14) .555
05 1.00 (0.65-1.52) .991 1.16 (0.32-4.16) .82
017 1.38 (1.07-1.78) .014 1.87 (0.72-4.86) .201
644 0.91 (0.63-1.31) .607 0.49 (0.10-2.33) .366
465 1.20 (0.85-1.69) .288 0.62 (0.07-5.16) .536
053 0.86 (0.70-1.05) .138 1.08 (0.59-2.41) .843
001 1.13 (0.68-1.87) .64 0.62 (0.07-5.16) .655
18 0.88 (0.55-1.42) .603 4.39 (1.38-13.96) .012
and HLA matching in HVG direction for rejection.
e, donor age, sex-matching disease, GVHD prophylaxis, total body
s of HLA and KIR ligand.stic
P
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3.35; P  .001), and both high-risk and standard-risk
ML had a signiﬁcantly lower relapse rate of HLA-
PB1 mismatch (HR  0.35; P  .001 and HR 
igure 1. Cumulative incidence of relapse and survival by matchi
able 4. Effects of HLA and KIR ligand matching for mortality
All Leukemia Cell Types
Acute Myelob
Leukemia
HR* 95% CI P HR 95% CI
LA-A 1.36 (1.16-1.59) <.001 1 (0.75-1.34
LA-B 1.40 (1.13-1.73) .002 1.43 (0.96-2.12
LA-C 1.17 (0.99-1.37) .067 1.18 (0.89-1.55
LA-DRB1 0.92 (0.74-1.15) .463 0.74 (0.50-1.10
LA-DQB1 1.28 (1.04-1.58) .018 1.29 (0.89-1.87
LA-DPB1 1.06 (0.91-1.23) .474 0.96 (0.75-1.24
IR2DL-G† 1.80 (1.39-2.34) <.001 1.93 (1.22-3.05
IR2DL-R‡ 1.07 (0.81-1.41) .612 1.08 (0.66-1.75
Hazard ratio of mismatch with match as a reference adjusted for pa
irradiation, transplanted cell dose, risk status, and other matchi
KIR2DL ligand mismatching in GVH direction.
KIR2DL ligand matching in HVG direction.olid line represents match; the dotted line, mismatch.
20.39; P  .012, respectively). No signiﬁcant effect
as observed in AML (HR  0.76; P  .137) or
LL (HR  0.92; P  .604).
LA-C in patients with ALL, AML, and CML. All patients were
Acute Lymphoblastic
Leukemia Chronic Myeloid Leukemia
HR 95% CI P HR 95% CI P
8 1.46 (1.11-1.90) .006 1.77 (1.35-2.33) <.001
9 1.47 (1.03-2.09) .036 1.18 (0.80-1.72) .402
6 0.99 (0.74-1.31) .928 1.42 (1.04-1.93) .025
6 1.04 (0.72-1.49) .849 0.99 (0.65-1.50) .951
4 1.33 (0.93-1.90) .108 1.18 (0.79-1.75) .422
2 1.33 (1.02-1.75) .038 0.97 (0.74-1.27) .827
5 1.57 (0.96-2.56) .069 2.23 (1.42-3.50) <.001
9 0.98 (0.59-1.61) .934 1.07 (0.66-1.72) .787
e, donor age, sex-matching disease, GVHD prophylaxis, total body
s of HLA and KIR ligand.ng of H
nalyzed. The direction of mismatching of HLA-C for relapse is GVH for relapse, and the direction for survival is GVH and/or HVG. Thelastic
P
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Effect of HLA and KIR Ligand in Leukemia Unrelated-BMT 321As shown in Figure 2, the relapse rate 5 years after
ransplantation was 7.1% (95% CI  5.0%-10.4%)
or HLA-DPB1 mismatch and 19.3% (95% CI 
4.3%-24.9%) for HLA-DPB1 match in CML pa-
ients (P  .001); 20.4% (95% CI  16.4%-24.8%)
nd 25.9% (95% CI 19.9%-32.2%), respectively, in
ML patients (P  .272); and 24.0% (95% CI 
9.9%-28.3%) and 30.2% (95% CI  23.7%-37.0%),
espectively, in ALL patients (P  .319).
Mismatch of HLA-A, -B, -DRB1, and -DQB1 was
ot a signiﬁcant risk factor for leukemia relapse by
ultivariate analysis (Table 2).
Patients with KIR-L-MM-G had a higher relapse
ate than those with KIR2DL ligand match in ALL
HR  2.55; P  .017) (Table 2). This adverse effect
n leukemia relapse was remarkable in high-risk ALL
HR  3.03; P  .013), but not in standard-risk ALL
igure 2. Cumulative incidence of relapse and survival by matching
nalyzed. The direction of mismatching of HLA-DPB1 for relapse
olid line, match; dotted line, mismatch.HR  1.11; P  .921). In AML and CML, KIR-L- dM-G had no effect on leukemia relapse (HR 1.05;
 .926 and HR  1.23; P  .727, respectively).
Because KIR-L-MM occurs in HLA-C mismatch
airs, the cumulative incidence of leukemia relapse
as analyzed in HLA-C mismatch patients in either
irection by leukemia cell type (Figure 3). The relapse
ate 5 years after transplantation was 31.0% (95% CI 
.6%-47.9%) for KIR-L-MM-G and 16.3% (95%
I  11.0%-22.4%) for match in ALL patients (P 
026); 11.1% (95% CI  3.5%-23.6%) and 11.8%
95% CI  7.4%-17.3%), respectively, in CML pa-
ients (P .634); and 12.9% (95% CI 4.1%-27.0%)
nd 16.3% (95% CI 11.0%-22.6%), respectively, in
ML patients (P  .757).
Signiﬁcant clinical risk factors for leukemia relapse
y multivariate analysis included status at transplanta-
ion (standard vs high, HR  3.00; P  .001) and
A-DPB1 in patients with ALL, AML, and CML. All patients were
for relapse, and the direction for survival is GVH and/or HVG.of HL
is GVHisease (HR 0.75; P .001) in all leukemia patients.
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3ffects of HLA Locus Mismatch and KIR Ligand
ismatch on Rejection
Rejection rates in patients who engrafted marrow
nd survived more than 21 days were analyzed. KIR-
-MM-R was found to be a signiﬁcantly higher risk
actor for rejection compared with match (HR 4.39;
 .012), and no HLA mismatch was considered
igniﬁcant by multivariate analysis (Table 3). Older
onor age was a signiﬁcant clinical risk factor for
ejection (HR  1.08; P  .002); other clinical factors
ere not signiﬁcant.
The cumulative incidence of graft rejection was
.7% (95% CI  2.3%-11.3%) in KIR-L-MM-R
n  106) and 1.8% (95% CI  0.8%-3.3%) in match
n  447) (P  .019) 1 year after transplantation in
igure 3. Cumulative incidence of relapse and survival by matching
ith ALL, AML, and CML. HLA-C–mismatched patients were sel
nd/or HVG. The solid line represents KIR2DL ligand match in
irection.LA-C–mismatched patients in either direction. En- a
22raftment rate was not inﬂuenced by HLA and KIR
igand matching (data not shown).
ffects of HLA Locus Mismatch and KIR Ligand
ismatch on Acute GVHD
HLA allele mismatch of each HLA-A, -B, and -C
ocus was found to be an independent risk factor for
rade 3-4 aGVHD and grade 2-4 aGVHD, and the
ismatch of each HLA-DRB1 and -DQB1 locus was
ot a signiﬁcant risk factor. HLA-DPB1 mismatch
as a signiﬁcant risk factor for grade 2-4 aGVHD and
marginal risk factor for grade 3-4 aGVHD (Table
). When analyzed by leukemia cell type, AML
howed no signiﬁcant HLA mismatch locus for
2DL ligand in the GVH direction in HLA-C–mismatched patients
r this analysis. The directions of HLA-C mismatching were GVH
VH direction; the dotted line, KIR2DL mismatch in the GVHof KIR
ected fo
the GGVHD (data not shown).
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Effect of HLA and KIR Ligand in Leukemia Unrelated-BMT 323KIR-L-MM-G was associated with a signiﬁcantly
igher risk of grade 2-4 aGVHD (HR  1.70; P 
001) and grade 3-4 aGVHD (HR  2.35; P  .001)
ompared with KIR ligand match (Table 3). By leu-
emia cell type, the HR of KIR-L-MM-G in grade
-4 aGVHD was 2.76 for AML (P  .005), 1.75 for
LL (P  .111), and 2.79 for CML (P  .001).
In HLA-C mismatch patients, the incidence of
0.3% in KIR-L-MM-G (95%CI 29.3%-50.9%) was
igniﬁcantly higher than the 25.8% in match (95%CI
1.9%-30.0%) (P  .011) for grade 3-4 aGVHD.
Signiﬁcant clinical risk factors for grade 3-4
VHD by multivariate analysis were GVHD prophy-
axis (tacrolimus vs cyclosporine, HR  0.72; P 
016), patient age (HR  0.99; P  .019), donor age
HR  1.02; P  .001), and disease (HR  1.28; P 
001) in all leukemia patients.
ffects of HLA Locus Mismatch and KIR Ligand
ismatch on Chronic GVHD
The occurrence of cGVHD was analyzed in pa-
ients who survived more than 100 days after trans-
lantation. HLA-A mismatch and HLA-C mismatch
ere found to be signiﬁcant factors (HR  1.41; P 
013 and HR  1.38; P  .014, respectively). KIR-L-
M-G was not signiﬁcant (HR  1.13; P  .640)
Table 3).
In HLA-C mismatch patients, the cumulative in-
idence of cGVHD 3 years after transplantation was
3.2% in KIR-L-MM-G (95% CI  27.2%-58.3%)
nd 40.4% in KIR2DL ligand match (95% CI 
5.4%-46.1%) (P  .727). Signiﬁcant clinical risk fac-
ors for cGVHD by multivariate analysis were patient
ge (HR  1.01; P  .0004), disease (HR  1.23; P 
003), and TBI (HR  1.54; P  .004).
ffects of HLA Allele Mismatch and KIR Ligand
ismatch on Survival
In all leukemia patients, HLA allele mismatch of
ach HLA-A, -B, and -DQB1 locus was found to be an
ndependent risk factor for mortality after transplan-
ation, and the mismatch of HLA-C was of marginal
isk. HLA mismatch in each HLA-DRB1 and -DPB1
ocus was not a signiﬁcant factor. By leukemia cell
ype, mismatch of HLA-A, -B, and -DPB1 was a
igniﬁcant risk factor in ALL, and mismatch of
LA-A and -C was a signiﬁcant risk factor in CML
Table 4).
Survival 5 years after transplantation was 39.8% in
LA-C mismatch (95% CI  32.8%-46.7%) and
4.5% in HLA-C match (95% CI 39.6%-49.3%) in
LL (P  .088); 33.7% (95% CI  26.9%-40.6%)
nd 46.3% (95% CI 41.2%-51.2%), respectively, in
ML (P  .001); and 39.7% (95% CI  32.8%-
6.5%) and 58.3% (95% CI 53.2%-63.1%), respec-
ively, in CML (P  .001) (Figure 1). mSurvival 5 years after transplantation was 40.9% in
LA-DPB1 mismatch (95% CI 36.3%-45.4%) and
0.3% in HLA-DPB1 match (95% CI  41.5%-
8.4%) in ALL (P  .031); 41.8% (95% CI  37.0%-
6.6%) and 42.6% (95% CI 34.5%-50.4%), respec-
ively, in AML (P  .698); and 51.4% (95% CI 
6.5%-56.1%) and 53.4% (95% CI  45.1%-61.0%),
espectively, in CML (P  .522) (Figure 2).
KIR-L-MM-G was also found to be a signiﬁcant
isk factor for mortality (HR  1.80; P  .001).
articularly in AML and CML patients, KIR-L-MM-G
ad a signiﬁcantly higher adverse effect than match
HR  1.93; P  .005 and HR  2.23; P  .001,
espectively); its effect was moderate in ALL patients
HR  1.57; P  .069) (Table 4).
In HLA-C mismatch patients in either direction,
he survival rate 5 years after transplantation was
0.0% for KIR-L-MM-G (95% CI  6.9%-38.0%)
nd 43.0% in match (95% CI  35.3%-50.5%) in
LL (P  .041); 19.4% (95% CI  7.9%-34.6%) and
6.5% (95% CI  28.8%-44.2%), respectively, in
ML (P  .013); and 22.2 (95% CI  10.5%-36.7%)
nd 43.6% (95% CI 35.8%-51.1%), respectively, in
ML (P  .001) (Figure 3).
Signiﬁcant clinical factors for mortality by multi-
ariate analysis were patient age (HR  1.02; P 
001), donor age (HR  1.01; P  .037), disease (HR 
.88; P .006), and the status at transplantation (high
s standard, HR  2.14; P  .001).
ISCUSSION
In the present study, we attempted to elucidate
ow disparities of HLA and KIR affect leukemia re-
apse and the other transplantation-related immuno-
ogic events and to explore how these ﬁndings can be
pplied to induce a GVL effect and improve patient
urvival in the unrelated setting. Simultaneous analysis
f HLA and KIR ligand matching by multivariate
nalysis made it possible to clarify the role of these
ntigens in UR-HSCT.
To the best of our knowledge, this is the ﬁrst
eport to elucidate the HLA locus responsible for the
VL effect by leukemia cell type in T-cell–replete
R-HSCT. The sequentially registered 577 AML,
17 ALL, and 596 CML patients sufﬁced to analyze
he effects of HLA and KIR ligand matching in the 3
ajor leukemia cell types.
HLA-C mismatch reduced the relapse rate overall,
s reported previously [4]. The GVL effect of HLA-C
ismatch depended on the leukemia cell type. ALL
atients with HLA-C mismatch showed a signiﬁcantly
ower leukemia relapse risk than those with match,
hereas AML and CML patients did not. Further-
ore, CML patients with HLA-DPB1 mismatch
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3howed a signiﬁcantly lower leukemia relapse rate
han those with match, whereas AML and ALL pa-
ients did not. Although the reason why the HLA
ocus responsible for the GVL effect differs with leu-
emia cell type remains unknown, the different ex-
ression of HLA antigens, such as HLA-C, HLA-
PB1, or co-stimulatory molecules on leukemia cells,
ight modify the immune response of effector cells to
eukemia cells. The ﬁnding of HLA-DPB1 is in line
ith a previous report in CML and ALL patients
reated with T cell–depleted UR-HSCT [12].
In contrast, an impact of HLA-A and -B allele
ismatch on leukemia relapse was not observed. Be-
ause HLA-A and/or -B allele mismatch induces se-
ere aGVHD, no GVL effect of HLA-A and /or -B
llele mismatch might imply that the target antigenic
eptide recognized by effector T cells responsible for
GVHD is not expressed on leukemia cells.
Unexpectedly, KIR-L-MM-G increased the leu-
emia relapse rate overall. A signiﬁcantly increased
elapse rate in the mismatched group was observed in
LL, but not in AML and CML. Simultaneous mul-
ivariate analysis of HLA-C mismatch and KIR-L-
M-G revealed that contrary reactions of these mis-
atches occurred independently. Although the
echanism involved in this detrimental effect of KIR-
-MM-G on leukemia relapse is not known, the ac-
ivation of KIR-positive NK cells or T cells might
ause immune dysfunction, which abrogates the GVL
ffect.
The GVL effect of donor-derived KIR-positive
K cells transplanted puriﬁed CD34 stem cells with
LA haploidentical donor was reported in AML pa-
ients, but not in ALL patients [22]. In T-cell–replete
R-HSCT, published reports show contradictory ef-
ects of KIR ligand mismatch on leukemia relapse. A
VL effect in myeloid malignancies [23-25], a higher
eukemia relapse rate [26], and no signiﬁcant effect
27-29] all have been reported. The use of ATG for
VHD prophylaxis might be a key to understanding
hese diverse results. Our analysis of T-cell–replete
R-BMT with no use of ATG provided reliable evi-
ence for the adverse effect of KIR-L-MM-G on
elapse of ALL relapse. No effect on relapse of AML
r CML was reported in a recent large-scale study of
yeloid malignancy from the Center for International
lood and Marrow Transplant Research, the Euro-
ean Blood and Marrow Transplant Registry, and the
utch Registry [30]. Whether KIR ligand match af-
ects leukemia relapse adversely or beneﬁcially is a
ritical issue for clinical transplantation and immuno-
herapy using NK cells, and further large-scale com-
arative studies considering GVHD prophylaxis are
arranted.
A higher rejection rate (HR  4.39; P  .012) wasound for KIR-L-MM-R; that is, in this mismatch m
24ombination, patient KIR2DL-positive effector cells
acking donor KIR ligand are reconstituted and acti-
ated after transplantation, which induces the rejec-
ion of engrafted donor-derived hematopoietic stem
ells. “Hybrid resistance” has been extensively ana-
yzed in mice to induce graft rejection by NK cells
31]. The same mechanism of rejection induced by
K cells might be considered in humans, although
8% of KIR ligand mismatch pairs and 86% of match
airs were given cyclophosphamide as a precondition-
ng. The effects of HLA class I mismatch for graft
ejection were reported [5,32,33]; our data suggest
hat the effect of HLA-C mismatch were mainly be-
ause of KIR2DL ligand mismatch in the HVG di-
ection, and may not result from the HLA-C allele
ismatch itself. Our ﬁndings are in agreement with a
eport showing the effect of rejection but not engraft-
ent by KIR2DL ligand mismatch in UR-HSCT
29].
Since the ﬁrst JMDP report [4], HLA-class I mis-
atch has been known to signiﬁcantly increase
GVHD, whereas HLA-DRB1 mismatch has only a
arginal effect on aGVHD. The present study has
onﬁrmed those earlier ﬁndings. We could add the
ew data on HLA-DPB1 matching showing that
LA-DPB1 mismatch induces moderate aGVHD.
ur ﬁnding of the effect of HLA-DPB1 on aGVHD
oncurs with other reports [9-11], although there we
ound no difference in aGVHD between 2 allele mis-
atches and 1 allele mismatch of HLA-DPB1.
The international collaborative study is expected
o reconcile discrepancies of allele matching in ethni-
ally diverse transplantation populations. Further-
ore, the identiﬁcation of nonpermissive HLA allele
ismatch and amino acid substitution responsible for
GVHD, leukemia relapse, and survival might explain
hese discrepancies in diverse ethnic populations.
Interestingly, KIR-L-MM-G had a higher HR of
evere aGVHD than did match. Because these values
ere adjusted by HLA allele matching and clinical
actors, this ﬁnding demonstrates that KIR-L-MM-G
s a factor independent of HLA allele matching. In
act, among HLA-C mismatch patients, KIR-L-
M-G was associated with a higher rate of grade 3-4
GVHD than match. In KIR-L-MM-G, the donor-
erived KIR2DL2/3- or KIR2DL1-positive effector
ells are suspected to react with patient cells that lack
he corresponding KIR2DL epitope of HLA-C.
hese effector cells induce aGVHD through several
ossible mechanisms. First, NK cells derived from
onor graft might directly attack the patient target
ells. This is unlikely, however, because in vivo infu-
ion of alloreactive NK cells were found to not cause
GVHD [34], and NK cells were seen to play mainly
protective role for GVHD in a murine experimental
odel [35]. Alternatively, activated NK cells might
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Effect of HLA and KIR Ligand in Leukemia Unrelated-BMT 325ffect donor-derived T cells that induce aGVHD.
hird, KIR2DL-positive T cells might induce
GVHD directly. The presence of KIR2DL-positive
cells was reconstituted after UR-HSCT [36].
Conﬂicting ﬁndings have been reported in terms
f the effect of KIR-L-MM-G on aGVHD in T-cell–
eplete UR-HSCT. Some studies have found a trend
oward less aGVHD [23], whereas others have re-
orted an increased risk of aGVHD [27,29]. The
ariety of GVHD prophylaxis, HLA matching, and
ther clinical factors, and limited patient numbers in
ach study makes it difﬁcult to determine the role of
IR ligand matching in clinical outcomes. The use of
TG and/or the T-cell depletion method for GVHD
rophylaxis will be a key strategy in resolving the
iscrepancy regarding aGVHD in UR-HSCT [35,37]
nd in HLA haplotype–identical related HSCT with
-cell depletion [38]. That is, T cell and NK-cell
econstitution after transplantation might affect im-
unologic events induced by the interaction of KIR
nd HLA-C epitopes. In addition, genotyping of KIR
enes, especially for activating KIR such as KIR2DS,
s required to understand the mechanism of KIR in-
olved in aGVHD and the GVL effect [39]. The East
sian population, including Japanese, is known to
ave several characteristic HLA types. Similarly, the
requencies of both the KIR ligand epitope and the
IR genotype are distinctive in the Japanese popula-
ion. For example, a higher frequency of C1 epitope
nd dominance of the KIR “A” haplotype were re-
orted [40]. Those features might contribute consid-
rably to our results. The combination of KIR2DL1
nd C2 epitope has been reported to show higher
fﬁnity and a stronger inhibitory signal compared with
he combination of KIR2DL2/3 and C1 epitope [14].
HLA-A and HLA-C mismatch have been identi-
ed as signiﬁcant independent factors inducing
GVHD, underscoring our previous ﬁnding of the
mportance of HLA class I matching. No inﬂuence of
IR-L-MM-G on cGVHD (in contrast to aGVHD)
ndicates that the KIR-related immunologic reaction
as no relation to cGVHD.
There is another model regarding the KIR ligand
ffect in HSCT, the so-called “missing KIR ligand
heory.” Hsu et al reported this effect on survival and
elapse of AML and myelodysplastic syndrome in T-
ell–depleted HLA-matched related HSCT [41] and
n relapse in AML, ALL, and CML in UR-HSCT in
on-JMDP populations [42]. Lack of either KIR2DL
igand in a patient should activate the corresponding
onor NK cells and induce the GVL effect.
In the analysis of KIR matching including HLA
ismatch pairs, the mismatch pairs in the “missing
IR ligand theory” with either C1C1 or C2C2 patient
pitope were divided into match and mismatch in the
KIR ligand matching theory” by donor epitope. Hhen the donor has either C1C1 or C2C2, the KIR
igand matching theory indicates match, and when the
onor has C1C2, the theory indicates mismatch. In
his combination, donors with C1C2 (n  92) had a
igniﬁcantly higher rate of severe aGVHD (44.4%)
han donors with either C1C1 or C2C2 (19.2%) (n 
413; P .001). Therefore, we considered the “ligand
atching model” to be applied in this JMDP study.
Finally, because survival after transplantation is
nﬂuenced not only by leukemia relapse, but also
y transplantation-related mortality resulting from
GVHD, cGVHD, fatal infections, or graft failure,
he effect of HLA matching and KIR ligand matching
hould be discussed in light of these events.
The present study has more precisely elucidated
he impact of HLA matching on leukemia patient
urvival. The mismatch of HLA-A and -B alleles re-
ulted in signiﬁcantly higher mortality. HLA-C and
LA-DQB1 mismatch emerged as a risk factor for
oorer survival for the ﬁrst time in the JMDP study.
ncreased survival in ALL with HLA-C mismatch
annot be linked to the compensation from a lower
eukemia relapse rate. HLA-DPB1 mismatch did not
igniﬁcantly affect overall mortality despite the in-
rease in moderately aGVHD. These observations of
LA-C and -DQB1 mismatch in the JMDP are in
ine with those of other recent reports. The NMDP
eported an adverse effect of HLA-C mismatch [8],
nd another study reported that not only HLA-C
ismatch in early-stage CML, but also HLA-DQB1
ismatched CML patients with multiple mismatch
osed increased risk for mortality [43].
It should be noted that KIR-L-MM-G resulted in
igher mortality in UR-HSCT with T-cell–replete
arrow regardless of leukemia cell type. KIR-L-
M-G might induce an immunodeﬁcient state that
ould result in a higher risk for opportunistic infec-
ions [44,45]. Thus, infectious complications by cyto-
egalovirus and the like should be explored in rela-
ion to KIR.
We estimate that about 30% of patients in the
apanese population have HLA-C mismatch donors,
f whom 15.0% are KIR-L-MM in the GVH direc-
ion, 20.8% are KIR-L-MM in the HVG direction,
nd 35.6% are KIR-L-MM in either direction, when
LA-A, -B, and -DRB1 genotyping is used as the
onor conﬁrmatory typing. Because both KIR2DL
igand matching and/or HLA matching itself affect
GVHD, cGVHD, rejection, ALL relapse, and sur-
ival, as described earlier, HLA-C typing is essential
n selecting a suitable donor to reduce the risk of
GVHD and improve survival in practice.
In conclusion, our analysis has produced impor-
ant ﬁndings for transplantation immunology and the
election of donors in UR-HSCT. First, HLA-C and
LA-DPB1 mismatches are expected to induce a ben-
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3ﬁcial GVL effect, which should be considered in
erms of the leukemia cell type of individual patients.
econd, KIR-L-MM should be avoided, because it
nduces only adverse effects on transplantation out-
ome and provides no beneﬁts for patients undergoing
-cell–replete UR-HSCT.
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